NCT05899738View on ClinicalTrials.gov

A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 18, 2023

Primary Completion Date

July 6, 2023

Study Completion Date

July 6, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

Iberdomide

Specified dose on specified days

Trial Locations (1)

32117

Local Institution - 0001, Daytona Beach

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY

NCT05899738 - A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants | Biotech Hunter | Biotech Hunter